The Claim
In patients with newly diagnosed Graves' disease, elevated thyroid-stimulating hormone receptor antibody (TRAb) levels ≥10.3 IU/L, free thyroxine (FT4) ≥56.7 pmol/L, and free triiodothyronine (FT3) ≥24.4 pmol/L are associated with a higher likelihood of disease relapse after antithyroid drug therapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Patients with newly diagnosed Graves' disease who have thyroid hormone and antibody levels above specific thresholds are more likely to experience a return of the disease after completing antithyroid drug treatment.
See the scientific wording
In patients with newly diagnosed Graves' disease, elevated thyroid-stimulating hormone receptor antibody (TRAb) levels ≥10.3 IU/L, free thyroxine (FT4) ≥56.7 pmol/L, and free triiodothyronine (FT3) ≥24.4 pmol/L are associated with a higher likelihood of disease relapse after antithyroid drug therapy, based on a retrospective case-control analysis of 188 patients.
High levels of antibodies bind to the thyroid gland and force it to produce too much thyroid hormone. The excess hormone overwhelms the body’s ability to shut off production, keeping the thyroid overactive even after treatment stops. This persistent overactivity prevents the gland from returning to normal function, causing the disease to return.
What the research says
1 studyDoctors found that new Graves' disease patients with very high levels of certain blood markers are much more likely to get sick again after stopping their medicine. So if these markers are high, it’s a warning sign the disease might come back.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.